Incidence of tuberculosis in HIV-infected patients receiving HAART: Interaction between TST and CD4 count

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 10, 2011, Pages 1347-1352

  Martín Echevarría, Esteban ^a   Rodriguez Zapata M ^a   Torralba, M ^a   Fernandez J M R ^b   Moreno, A ^b   Casado, J L ^b   Dronda, F ^b   Perez Elias M J ^b   Navas, E ^b   Moreno, S ^b  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiretroviral therapy; CD4 count; HIV; PPD; Tuberculin skin test; Tuberculosis

Indexed keywords

ADULT; ARTICLE; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TUBERCULIN TEST; TUBERCULOSIS; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; COINFECTION; DISEASE-FREE SURVIVAL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; TIME FACTORS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 80053191776     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0686     Document Type: Article

References (34)

1. Palella F J Jr, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860. (Pubitemid 28135961)
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129. (Pubitemid 34786200)
3. Jones J L, Hanson D L, Dworkin M S, De Cock K M; Adult/ Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2000; 4: 1026-1031.
4. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
5. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2220-2226. (Pubitemid 30002965)
6. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064. (Pubitemid 34680968)
7. Santoro-Lopes G, De Pinho A M, Harrison L H, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546. (Pubitemid 34112278)
8. Lawn S D, Bekker L G, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19: 1113-1124. (Pubitemid 41059253)
9. Raviglione M C, Snider D E Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
10. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 2007; 21: 2521-2527. (Pubitemid 350145184)
11. Centro Nacional de Epidemiología. Vigilancia Epidemiológica del Sida en España. Situación a 30 de junio de 2002. Registro Autonómicos de Casos de Sida. Madrid, Spain. Dirección General de Salud Pública y Sanidad Exterior & Institute de Salud Carlos III, Government of Spain. Bol Epidemiol Semanal 2002; 10: 121-124. [Spanish]
12. Antonucci G, Girardi E, Raviglione M C, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274: 143-148.
13. Scholten J N, Driver C R, Munsiff S S, et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis 2003; 37: 1686-1692. (Pubitemid 37549957)
14. Graham N M, Nelson K E, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992; 267: 369-373.
15. Blatt S P, Hendrix C W, Butzin C A, et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIVi nfected patients. Ann Intern Med 1993; 119: 177-184. (Pubitemid 23327616)
16. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47 (RR-20): 1-58.
17. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developingtuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119: 194-198. (Pubitemid 23327618)
18. Arnadottir T, Rieder H L, Trébucq A, Waaler H T. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tubercle Lung Dis 1996; 77 (Suppl 1): 1-19. (Pubitemid 26285466)
19. Castro K G, Ward J W, Slutsker L, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR-17): 1-19.
20. Grupo de trabajo del PMIT. Incidencia de la tuberculosis en España: resultados del Proyecto Multicéntrico de investigación en Tuberculosis (PMIT). Med Clin (Barc) 2000; 114: 530-537. [Spanish]
21. Rey R, Ausina V, Casal M, et al. [Current status of tuberculosis in Spain. A precarious health care perspective with regard to developed countries]. Med Clin (Barc) 1995; 105: 703-707. [Spanish]
22. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550. (Pubitemid 19070537)
23. Selwyn P A, Sckell B M, Alcabes P, Friedland G H, Klein R S, Schoenbaum E E. High risk of active tuberculosis in HIVi nfected drug users with cutaneous anergy. JAMA 1992; 268: 504-509.
24. Chin D P, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. The Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1996; 153: 1982-1984. (Pubitemid 26187930)
25. Markowitz N, Hansen N I, Hopewell P C, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1997; 126: 123-132. (Pubitemid 27058586)
26. Gordin F M, Matts J P, Miller C, et al. A controlled trial ofisoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337: 315-320. (Pubitemid 27318993)
27. Whalen C C, Johnson J L, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-808. (Pubitemid 27391629)
28. Perez-Hoyos S, Rodriguez-Arenas M A, Garcia de la Hera M, et al. Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort. J Womens Health (Larchmt) 2007; 16: 1052-1061. (Pubitemid 47479949)
29. Mosimaneotsile B, Mathoma A, Chengeta B, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience, 2004-2006. J Acquir Immune Defic Syndr 2010; 54: 71-77.
30. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1: CD000171.
31. Pai M, Riley L W, Colford J M Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: 761-776.
32. Hill P C, Brookes R H, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38: 966-973. (Pubitemid 38457204)
33. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354. (Pubitemid 351650594)
34. Bua A, Molicotti P, Ruggeri M, et al. Interferon gamma release assay in people infected with immunodeficiency virus. Clin Microbiol Infect 2011; 17: 402-404.